Stellar Health’s Tech-Enabled ACO Saves Medicare $5.0 Million in Inaugural 2024 Performance Year

The model validates a unique and transparent approach for delivering tangible financial success for practices and providers everywhere. Stellar Health, a healthcare technology company focused on redefining value-based care delivery and reimbursement, today announced that its wholly-owned MSSP Accountable Care Organization (shaco), generated $5.0 Million in gross savings for Medicare. This included $2.45 million in […]

Medunik USA strengthens Pheburane® (sodium phenylbutyrate) coverage under Medicaid Programs

Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs, and part of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, is pleased to announce thatPheburane®(sodium phenylbutyrate) is now covered under Preferred Medicaid Programs in 19 states, while 29 states offer it

IAS and Snap Announce Expansion of Measurement Partnership to Validate Ad Effectiveness in Sponsored Snaps

Adds Viewability and Invalid Traffic (IVT) Measurement for Chat Feed; Now Enabling IAS Coverage Across all Snapchat Ad Formats on any Device Integral Ad Science (Nasdaq: IAS), a leading global media measurement and optimization platform, today announced the expansion of its measurement partnership with Snap Inc. (NYSE: SNAP) to give advertisers greater tools to validate

Keystone Venture Trust Inc. Enters U.S. Financial Market with New York Launch and Colorado Branch

Keystone Venture Trust Inc. Enters U.S. Financial Market with New York Launch and Colorado Branch GlobeNewswire November 04, 2025 NEW YORK, USA, Nov. 04, 2025 (GLOBE NEWSWIRE) — Keystone Venture Trust Inc., a global financial asset management firm, today announced its official entry into the United States market with the opening of a new office

Firstsource Strengthens UnBPO™ Vision with Strategic Investment in Lyzr.ai

Firstsource Solutions Limited(NSE: FSL) (BSE: 532809), a leading global provider of business process management services and anRP-Sanjiv Goenka Group company, today announced a strategic investment in Lyzr.ai, a cutting-edge enterprise AI agent infrastructure platform that enables organizations to build secure, reliable, and interconnected AI agents anchored by comprehensive knowledge bases, orchestration, and robust responsible AI

$100 Million Deal Positions This Microcap at the Crossroads of Biotech and Digital Finance

The worlds of biotechnology and cryptocurrency are colliding in unprecedented ways. Once viewed as niche markets, digital assets are increasingly finding a role in corporate treasuries, offering liquidity, optionality, and alternative financing structures for companies with long development cycles. In an industry where early-stage biotechs often struggle to secure funding without excessive dilution, leveraging blockchain-based

Lindblad Expeditions Holdings, Inc. Reports 2025 Third Quarter Financial Results

Third Quarter 2025 Highlights: — Total revenue increased 17% to $240.2 million — Net loss available to stockholders was $49 thousand — Adjusted EBITDA increased 25% to $57.3 million — Lindblad segment net yield per available guest night increased 9% to $1,314 — Occupancy increased to 88% from 82% — The Company refinanced its long-term

NATIONAL GEOGRAPHIC-LINDBLAD EXPEDITIONS EXPANDS ITS RIVER COLLECTION WITH NEW ITINERARIES AND RETURNING FAVORITES FOR 2027-2028

Demand drives expanded portfolio of river itineraries, including new holiday voyages in Europe Underscoring Lindblad Expeditions' continued investment in small-ship exploration along the world's most storied waterways, National Geographic-Lindblad Expeditions today announced an expanded 2027-2028 season for its growing collection of river cruise itineraries. https://mma.prnewswire.com/media/2516806/National_Geographic___Lindblad_Expeditions_Logo.jpg The 2027-2028 season marks the most expansive lineup of river

Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab ATNM-400 demonstrates efficacy across prostate cancer, non-small cell lung cancer (NSCLC), and breast cancer – three of the largest oncology indications – with potential as monotherapy, in combination, or

Scroll to Top